Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and assessed whether response was related to EGFR amplification and/or concomitant use of enzyme-inducing antiepilep...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yung, W.K. Alfred, Vredenburgh, James J., Cloughesy, Timothy F., Nghiemphu, Phioanh, Klencke, Barbara, Gilbert, Mark R., Reardon, David A., Prados, Michael D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2010
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018931/
https://ncbi.nlm.nih.gov/pubmed/20615922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky